These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 23756322)

  • 1. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Zazo H; Martín-Suárez A; Lanao JM
    Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.
    Lepe JA; García-Cabrera E; Gil-Navarro MV; Aznar J
    Rev Esp Quimioter; 2012 Jun; 25(2):134-8. PubMed ID: 22707102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations.
    Khachman D; Conil JM; Georges B; Saivin S; Houin G; Toutain PL; Laffont CM
    J Antimicrob Chemother; 2011 Aug; 66(8):1798-809. PubMed ID: 21653603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
    Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
    Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia.
    Bernabeu-Wittel M; Pichardo C; García-Curiel A; Pachón-Ibáñez ME; Ibáñez-Martínez J; Jiménez-Mejías ME; Pachón J
    Clin Microbiol Infect; 2005 Apr; 11(4):319-25. PubMed ID: 15760430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of higher doses of amikacin in early stages of sepsis in critically ill patients.
    Najmeddin F; Ahmadi A; Mahmoudi L; Sadeghi K; Khalili H; Ahmadvand A; Najafi A; Mojtahedzadeh M
    Acta Med Iran; 2014; 52(9):703-9. PubMed ID: 25325208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis].
    Halacová M; Průsa R; Kotaska K; Vávrová V
    Cas Lek Cesk; 2004; 143(3):187-90. PubMed ID: 15134039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii.
    Ghazi IM; Grupper M; Nicolau DP
    Infect Dis (Lond); 2017; 49(11-12):831-839. PubMed ID: 28758820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models.
    Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Shigemi A; Umezaki Y; Nakamura K; Ueno K; Morikawa N; Takeda Y
    Int J Antimicrob Agents; 2014 Jun; 43(6):547-52. PubMed ID: 24796218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
    Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Morikawa N; Takeda Y
    J Infect Chemother; 2015 Apr; 21(4):284-9. PubMed ID: 25638291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
    Mouton JW; Punt N; Vinks AA
    Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.
    Kato H; Hagihara M; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
    Drugs R D; 2017 Mar; 17(1):177-187. PubMed ID: 28063020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
    Dong H; Wang X; Dong Y; Lei J; Li H; You H; Wang M; Xing J; Sun J; Zhu H
    Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
    Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.
    Jaruratanasirikul S; Wongpoowarak W; Wattanavijitkul T; Sukarnjanaset W; Samaeng M; Nawakitrangsan M; Ingviya N
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7236-7244. PubMed ID: 27671056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
    Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
    J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.